More Articles

Physician perceptions of generics substitution Biosimilars/Research | Posted 27/01/2012

How do physicians perceive generics substitution? Many patients do not communicate with their physicians regarding out-of-pocket expenses or medication choices. Therefore, understanding physicians’...

Roche encounters manufacturing issues with epoetin-beta Biosimilars/News | Posted 27/01/2012

The Spanish regulatory agency has found deviations in the quality of the manufacture of Switzerland-based F. Hoffmann-La Roche’s biological anaemia treatment Mircera (methoxy polyethylene glycol-ep...

Which drugs are affected by drug shortages in the US Reports | Posted 27/01/2012

Drug products on the shortages list in the US are concentrated into a small number of disease areas, according to a new report published by IMS Institute for Healthcare Informatics (IMS Institute)...

Watson expands in Asia with Ascent Pharmahealth Generics/News | Posted 27/01/2012

US generics manufacturer Watson Pharmaceuticals announced on 24 January 2012 that it had acquired Ascent Pharmahealth, the Australia and Southeast Asia generics subsidiary of Strides Arcolab, in a...

Australia’s biggest-ever generics price cuts coming in April 2012 Policies & Legislation | Posted 27/01/2012

On 1 April 2012, the prices of 75 medicines supplied through Australia’s Pharmaceutical Benefits Scheme (PBS) will be reduced by an average of 28.7%, saving the government an estimated Australian d...

Drug shortage woes continue in the UK Pharma News | Posted 27/01/2012

Despite attempts to solve problems with shortages of brand-name medicines in the UK, the issue is far from beings resolved. The latest news is that the UK’s wholesalers have called for a ‘third-par...

World Generic Medicines Congress Europe 2012 Conferences | Posted 27/01/2012

World Generic Medicines Europe Congress attracts attendees from leading generic pharma manufacturers, investment banks, pharmaceutical wholesale, law firms and API manufacturers to discuss the late...

Relative effectiveness and cost minimisation for biosimilars Biosimilars/Research | Posted 20/01/2012

The second of two articles on the use of economic evaluations to guide the use of expensive treatment.